What changed
FDA’s GLP-1 active-ingredient alert carries an October 9 revision and describes detention and Green List provisions.
What the evidence does not settle
Firm, product and exception scope cannot be generalized to all GLP-1 imports.
Evidence record
Event date: 2026-10-09. Source review: inherited source synthesis; not re-audited in this expansion. Editorial publication: 2026-10-29. Original source links below retain their publication dates. These dates are not interchangeable. This is targeted source synthesis, not an exhaustive archive or a qualified clinical/legal review.
Revision history
29 October 2026: migrated from the research edition, retaining source links and evidence qualifications; not re-audited in the current expansion. Report a proposed correction through Contact us; do not include patient data.